Unibest
← Back to patent-cliff list

CAS 619-42-1

methyl 4-bromobenzoateMethyl 4-bromobenzoate

Codes: PEME-009, Bromfenac Sodium-033

Application context (from source-drug indications)

Non-small cell lung cancerPemetrexed Disodium Hydrate间皮组织肿瘤Pemetrexed Disodium Hydrate胸膜孤立性纤维瘤Pemetrexed Disodium HydrateBladder cancerPemetrexed Disodium HydrateUrothelial carcinomaPemetrexed Disodium HydrateSolid tumourPemetrexed Disodium HydrateInflammatory diseaseBromfenac SodiumPostoperative painBromfenac Sodium眼睛发炎Bromfenac Sodium眼睛疼痛Bromfenac SodiumDry eye syndromeBromfenac Sodium黄斑水肿Bromfenac Sodium

Source drugs (routes using this intermediate)

DrugTierExpiry
Pemetrexed Disodium HydrateTier B — Position early-
Bromfenac SodiumTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.